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1. Introduction 
The discovery of etravirine 1 (TMC125, Fig. 1) is a 
comprehensive result of the coordinated multidisciplinary 
endeavor lasting for more than 20 years of research on non-
nucleoside reverse transcriptase inhibitors (NNRTIs).1 This 
promising NNRTI was approved by the FDA in 2008 for AIDS 
therapy owing to potency against both wild-type (WT) and 
mutant virus strains. Another clinical candidate NNRTI, VRX-
480773 22 (Fig. 1) originated from high-throughput screening 
(HTS) of compound libraries as a second generation NNRTI, 
showed resilience to the most NNRTI-resistant clinical HIV-1 
isolates. However, there is still a great need for additional new 
chemical entities with improved affinity and efficacy profiles and 
higher genetic barriers to resistance. 
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Figure 1. Structures of etravirine and VRX-480773. 
 
Figure 2. Superposition of lower-energy docking binding 
conformations of etravirine (purple) and VRX-480773 (blue) in the 
binding pocket of HIV-1 RT (protein removed for clarity). 
The present work is an extension of our ongoing efforts 
towards developing effective NNRTIs through a hybrid 
pharmacophore approach3-5, and one that uses etravirine and 
VRX-480773 as a starting point. Our docking model of 
overlaying the lower-energy conformations of etravirine and 
VRX-480773 templates within the NNRTIs binding sites 
(NNIBS) reveals that most fragments in the structures can  
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Figure 3. Design of etravirine–VRX-480773 hybrids 3 based on structure-guided molecular hybridization. 
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Scheme 1. Synthetic route of target compounds 3a-u. Reagents and conditions: (a) 4-hydroxy-3,5-dimethylbenzonitrile, NaH, THF, 40 oC, 6 h; 
(b) thiourea, EtOH, reflux, 4.5 h; (c) substituted α-bromoacetamide 7a-u, KOt-Bu, DMF, r.t., 1 h. 
 
Table 1 
Biological activities of compounds 3a-u in MT-4 cellsa 
Compounds R EC50b (μΜ) CC50c (μΜ) SId 
ⅢB K103N + Y181C HIV-2 
3a H > 320 > 320 > 320 > 320 1 
3b 3-F 8.1 ± 0.5 > 306 > 306 > 306 > 38 
3c 4-F 8.0 ± 2.4 > 306 > 306 > 306 > 38 
3d 2-Cl 0.24 ± 0.05 ≥ 10.9 > 294 > 294 > 1225 
3e 3-Cl 8.0 ± 2.3 > 294 > 294 > 294 > 37 
3f 4-Cl 3.9 ± 1.9 > 294 > 294 > 294 > 75 
3g 2,4-DiCl 1.2 ± 0.6 > 272 > 272 > 272 > 227 
3h 3,4-DiCl 5.3 ± 1.4 > 89 > 89 89 ± 7 17 
3i 3,5-DiCl 10.8 ± 2.8 > 41 > 41 ≥ 41 > 3.7 
3j 4-Br 1.4 ± 0.3 > 24 > 24 24 ± 3.7 17 
3k 2-NO2 0.34 ± 0.04 > 287 > 287 > 287 > 844 
3l 3-NO2 41 ± 7 > 287 > 287 > 287 > 7 
3m 4-NO2 1.4 ± 0.3 > 287 > 287 > 287 > 205 
3n 4-CN 4.3 ± 0.7 > 301 > 301 > 301 > 70 
3o 2-F-4-CN 6.0 ± 1.3 > 288 > 288 > 288 > 48 
3p 4-SO2NH2 7.9 ± 1.9 > 266 > 266 > 266 > 34 
3q 2-Me 5.9 ± 1.7 > 309 > 309 > 309 > 52 
3r 4-Me 5.1 ± 1.0 > 309 > 309 > 309 > 61 
3s 2-Me-4-SO2NH2 0.81 ± 0.19 > 46 > 46 46 ± 12 57 
3t 4-MeO 7.3 ± 1.3 > 69 > 69 ≥ 69 ≥ 9 
3u 4-OH 8.3 ± 1.3 > 71 > 71 71 ± 17 9 
DEV  0.66 ± 0.61 > 44 NDe > 44 > 67 
ETV  0.0041 ± 0.0002 0.025 ± 0.002 ND > 4.6 > 1122 
a All data represent man values for at least three separate experiments. 
b EC50: effective concentration required to protect the cell against viral cytopathicity by 50% in MT-4 cells. 
c CC50: cytotoxic concentration of compound that reduces the normal uninfected MT-4 cell viability by 50%. 
d SI: selectivity index, ratio CC50/IC50 (WT). 
e ND: not detected. 
 
superpose well with each other (Fig. 2). They exhibit similar 
binding patterns with HIV-1 RT (Fig. 2). In this paper, a 
series of etravirine–VRX-480773 hybrids 3 (Fig. 3), 
characterized by a 2,6-dimethyl-4-cyanophenoxyl group, a 
central pyrimidine ring and thioacetanilide moieties, were 
synthesized and evaluated as novel NNRTIs. Preliminary 
structure-activity relationships (SARs) and molecular 
modeling for these hybrids are also discussed. 
2. Chemistry 
The synthetic route for the target compounds 3a-u is 
depicted in Scheme 1. Biaryl ether 5 was obtained by 
regioselective coupling of 2,6-dimethyl-4-cyanophenol to 
the 4-position of 2,4-dichloropyrimidine (4).6 Treatment of 
2-chloropyrimidine 5 with thiourea yielded 2-
mercaptopyrimidine 6.7 Further condensation with known 
intermediates α-bromoacetamide 7a-u8 created the desired 
target compounds with yields of 48–86%. 
3. Results and discussion 
3.1. Biological activity 
The newly synthesized etravirine–VRX-480773 hybrids were 
evaluated for their anti-HIV activity in MT-4 cell cultures 
infected with a WT HIV-1 strain (ⅢB), a double mutant HIV-1 
strain RES056 (K103N + Y181C) or an HIV-2 strain (ROD). 
The results were expressed as cytotoxicity (CC50), anti-HIV 
activity (EC50) and selective index (SI = CC50/EC50). The SI 
indicates the specificity of the antiviral effect. The results are 
illustrated in Table 1, and include those of the two FDA 
approved drugs, delavirdine (DEV) and etravirine (ETV), as the 
reference standards. 
As listed in Table 1, these hybrids (except for compound 3a) 
were found to exhibit anti-HIV-1 ⅢB activity in the lower 
micromolar range (EC50 = 0.24–41 μΜ) with SI values ranging 
from 1 to > 1225. Compound 3d was the most potent inhibitor 
with an EC50 value of 0.24 μΜ against WT HIV-1. This activity 
was superior to that of the reference compound DEV (EC50 = 
0.66 μΜ, SI > 67), but inferior to that of ETV (EC50 = 0.0041 
μΜ) and VRX-480773 (EC50 = 0.00014 μΜ2). It is worth 
noting that analogues 3k (EC50 = 0.34 μΜ, SI > 844) and 3s 
(EC50 = 0.81 μΜ, SI = 57) possessed the same inhibitory 
activity as DEV against WT HIV-1. However, these hybrids 
lack potency against the double mutant strain RES056 and 
HIV-2. The preliminary SARs analyses indicated that the 
substitution pattern on the right wing of the hybrids might play 
a determinant role in their anti-HIV-1 (ⅢB) activity. All 
phenyl-substituted hybrids were more potent than the non-
substituted parent compound 3a, regardless of the electronic 
effect and steric bulk. In the case of di-substitution over mono-
substitution of the phenyl ring, 2,4-dichloro-substituted 3g 
(EC50 = 1.2 μΜ) showed no marked improvement on the ability 
to inhibit WT virus compared with 2-chloro (3d) and 4-chloro 
(3f) analogues (EC50 = 0.24 and 3.9 μΜ, respectively), with the 
exception of a 10-fold boost in activity achieved when a second 
methyl group was introduced in compound 3s. The inhibitory 
potency was higher for the ortho-substituted derivatives (3d 
and 3k) than for the para-substituted analogues (3f and 3m) 
that in turn was more active than the meta-substituted 
congeners (3e and 3l). For the compounds with a mono-
substituent at the C-4 position of the phenyl ring, the electron-
withdrawing groups (3j, 3m, 3f and 3n) seem to be more 
advantageous than the electron-donating substituents (3r and 
3t). Derivatives with hydrophobic groups (3n and 3r) were 
more potent than analogs with hydrophilic substituents (3p and 
3u). 
With the aim to verify their binding target, three selected title 
compounds (3d, 3k, and 3s) were assessed in enzyme assays9,10 
against highly purified recombinant HIV-1 RT using 
poly(rA)/oligo(dT)16 as template and primer, nevirapine (NVP) 
and efavirenz (EFV) as reference (Table 2). All the tested 
compounds showed moderate inhibitory activity against WT 
HIV-1 RT. The results confirmed the SAR information 
obtained in antiviral evaluation in MT-4 cells. As an example, 
compound 3d still displayed the highest inhibitory activity 
against WT HIV-1 RT with IC50 value of 0.473 μM, which was 
higher than nevirapine (NVP, IC50 = 0.807 μM), but lower than 
efavirenz (EFV, IC50 = 0.022 μM). These data suggest that 
these hybrids bind to HIV-1 RT and belong to HIV-1 NNRTIs. 
 
Table 2 
Inhibitory activity of representative hybrids against WT HIV-1 RTa 
Compounds IC50b (μM) 
3d 0.473 ± 0.155 
3k 1.169 ± 0.216 
3s 2.775  ± 0.117 
NVP 0.807  ± 0.326 
EFV 0.022 ± 0.006 
a Data represent the mean values of at least two separate experiments.  
b IC50: inhibitory concentration required to inhibit biotin deoxyuridine 
triphosphate (biotin-dUTP) incorporation into the HIV-1 RT by 50%. 
 
3.2. Molecular simulation 
To investigate the HIV-1 inhibitory potencies of the newly 
synthesized etravirine–VRX-480773 hybrids at a molecular 
level, molecular simulation was carried out. This was done by 
docking the representative compound 3a into the NNIBS of 
WT HIV-1 RT (PDB code: 3C6T)11 using a Base-Builder 
program and Surflex-Dock program interfaced with SYBYL-X 
1.2. The results are shown in Fig. 4. The hybrid 3a was 
predicted to bind with NNIBS in a “U” mode. Notable features 
include: (1) the left phenyl ring fitted into the aromatic-rich 
binding pocket, which was surrounded by the aromatic side 
chains of amino acid residues Tyr181, Tyr188 and Trp229, and 
exhibited π–π stacking interaction with these residues; (2) the 
right aromatic ring extended to the enzyme/water interfaces and 
made lipophilic interactions with the amino acids Phe227, 
Pro236 and Tyr318; (3) a hydrogen bond was formed between 
the NH group of the C2 side chain of hybrid 3a and the 
backbone C=O of Lys103, improving the affinity between RT 
and inhibitors. 
 
 
Figure 4. Predicted binding mode of the representative hybrid 3a 
in NNIBS of WT HIV-1 RT (PDB code: 3C6T). 
 
In summary, the computational modeling study was 
helpful to better understand the interactions between the 
hybrids and HIV-1 RT. The molecular binding model of 
compounds 3a provided critical insights for further 
development of these hybrids. 
4. Conclusion 
Based on a structure-guided molecular hybridization 
approach, we designed and synthesized a novel series of 
etravirine–VRX-480773 hybrids as potent HIV-1 NNRTIs. 
These hybrids were assessed for their anti-HIV-1 activity in 
MT-4 cell cultures. Most compounds (except for compound 3a) 
exhibited significant potency against WT HIV-1 strain (IIIB) at 
micromolar concentrations (EC50 = 0.24–41 μΜ). Among them, 
compound 3d displayed the highest activity with an EC50 value 
of 0.24 μΜ and SI > 1225. Taking full use of the information 
from SAR analyses and molecular modeling calculations, 
further optimization of this series of hybrids to improve their 
drug resistance profiles are ongoing and will be reported. 
5. Material and methods 
5.1. Chemistry 
Chemical reagents and solvents, purchased from commercial 
sources, were of analytical grade and were used without further 
purification. All air-sensitive reactions were run under a 
nitrogen atmosphere. All the reactions were monitored by TLC 
on pre-coated silica gel G plates at 254 nm under a UV lamp 
using ethyl acetate/hexane as eluent. Column chromatography 
separations were performed with silica gel (300–400 mesh). 
Melting points were measured on a SGW X-1 microscopic 
melting point apparatus. 1H NMR and 13C NMR spectra were 
recorded on a Bruker AV400 MHz spectrometer in DMSO-d6. 
Chemical shifts were reported in δ (ppm) units relative to the 
internal standard tetramethylsilane (TMS). Mass spectra and 
HRMS were obtained on a Waters Quattro Micromass 
instrument and Bruker solari X-70 FT-MS instrument, 
respectively, using electrospray ionization (ESI) techniques. 
The purities of target compounds were ≥ 95%, measured by 
HPLC, performed on an Agilent 1200 HPLC system with UV 
detector and Agilent Eclipse Plus C18 column (150 × 4.6 mm, 5 
μm), eluting with a mixture of solvents H2O (A) and CH3CN 
(B) from VA: VB = 90:10 to 10:90. Peaks were detected at λ 254 
nm with a flow rate of 1.0 mL/min. 
5.2. Preparation of 4-((2-chloropyrimidin-4-yl)oxy)-3,5-
dimethylbenzonitrile (5) 
Sodium hydride (2.20 g, 55 mmoL) was added in portion to a 
solution of 4-hydroxy-3,5-dimethylbenzonitrile (7.35 g, 50 
mmoL) in anhydrous THF (100 mL) at room temperature.6 The 
resulting solution was stirring for 10 min, then 2,4-
dichloropyrimidine (4) (7.40 g, 50 mmoL) was added. The 
reaction mixture was heated to 40 oC and maintained for 6 h. 
The progress of the reaction was monitored by TLC. After 
completion of the reaction, the reaction mixture was cooled to 
RT, poured into vigorously stirred ice water (800 mL), filtered 
the precipitated solid, washed with chilled water, and dried at 
50 oC under vacuum. The corresponding crude product was 
recrystallized from DMF to afford pure 5 (71% yield) as white 
crystals. Mp 230.3–230.9 oC; 1H NMR (400 MHz, DMSO-d6) δ 
= 2.08 (s, 6H, 2CH3), 7.28 (d, J = 5.6 Hz, 1H, pyrimidine H5), 
7.71 (s, 2H, PhH3,5), 8.67 (d, J = 5.6 Hz, 1H, pyrimidine H6); 
13C NMR (100 MHz, DMSO-d6) δ = 15.79, 107.14, 109.27, 
118.50, 132.49, 132.98, 152.34, 159.29, 162.13, 168.63; MS 
(ESI+) m/z 260 (M+H)+; HRMS calcd for C13H10ClN3O 
[M+Na]+: 282.0410, found: 282.0409. 
5.3. Preparation of 4-((2-mercaptopyrimidin-4-yl)oxy)-3,5-
dimethylbenzonitrile (6) 
4-((2-chloropyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile (5) 
(4.26 g, 16.4 mmoL), thiourea (1.88 g, 24.6 mmoL) and ethanol 
(75 mL) were boiled under reflux for 4.5 h.7 After the mixture 
was cooled, the precipitate was collected by filtration, washed 
with EtOH (2 × 10 mL) and dried at 50 oC under vacuum to 
give compounds 4-((2-mercaptopyrimidin-4-yl)oxy)-3,5-
dimethylbenzonitrile (6) as a white solid. Yield: 77%. Mp 
290.2–290.5 oC; 1H NMR (400 MHz, DMSO-d6) δ = 2.09 (s, 
6H, 2CH3), 6.61 (d, J = 6.8 Hz, 1H, pyrimidine H5), 7.69 (s, 
2H, PhH3,5), 7.99 (d, J = 6.8 Hz, 1H, pyrimidine H6); 13C NMR 
(100 MHz, DMSO-d6) δ = 15.94, 98.03, 108.89, 118.64, 
132.49, 132.73, 149.25, 152.71, 166.13, 182.38; MS (ESI+) m/z 
258 (M+H)+; HRMS calcd for C13H11N3OS [M+H]+: 258.0701, 
found: 258.0698. 
5.4. General procedure for the preparation of 3a-u 
Potassium tert-butoxide (0.0589 g, 0.525 mmoL) was added 
to a solution of 4-((2-mercaptopyrimidin-4-yl)oxy)-3,5-
dimethylbenzonitrile (6) (0.1287 g, 0.50 mmoL) in 1.5 mL of 
anhydrous DMF. The mixture was stirred for 30 min before 
0.50 mmoL of known intermediate α-bromoacetamide 7a-u8 
was added dropwise as a solution in 0.6 mL of anhydrous DMF 
and the reaction was stirring at room temperature for 1 h. The 
reaction was followed by TLC until its completion and water 
(21 mL) was added. The mixture was extracted with ethyl 
acetate (3 × 20 mL), washed with water (3 × 10 mL) and brine 
(3 × 10 mL), and dried over Na2SO4 to give the corresponding 
crude product, which was purified by flash column 
chromatography to afford compounds 3a-u. 
5.4.1. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-phenylacetamide (3a) 
Yield 76%; white solid, mp 211.2–211.6 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.98 (s, 6H, 2CH3), 3.78 (s, 2H, CH2), 
6.92 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.07 (m, 1H, Ph’H4), 
7.31 (m, 4H, PhH3,5 + Ph’H3,5), 7.54 (d, J = 6.4 Hz, 2H, 
Ph’H2,6), 8.54 (d, J = 5.6 Hz, 1H, pyrimidine H6), 9.91 (s, 1H, 
NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.74, 35.21, 
103.18, 108.78, 118.59, 118.76, 123.21, 128.75, 132.14, 
132.51, 139.27, 152.36, 159.90, 165.26, 166.95, 170.75; MS 
(ESI+) m/z 391 (M+H)+; HRMS calcd for C21H18N4O2S 
[M+Na]+: 413.1048, found: 413.1042; HPLC: tR = 8.21 min, 
99.2%. 
5.4.2. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(3-fluorophenyl)acetamide (3b) 
Yield 75%; white solid, mp 204.6–205.4 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.97 (s, 6H, 2CH3), 3.78 (s, 2H, CH2), 
6.88-6.94 (m, 2H, pyrimidine H5 + Ph’H4), 7.24 (m, 1H, Ph’H5), 
7.34-7.38 (m, 3H, PhH3,5 + Ph’H6), 7.51 (d, J = 11.2 Hz, 1H, 
Ph’H2), 8.54 (d, J = 5.6 Hz, 1H, pyrimidine H6), 10.11 (s, 1H, 
NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.72, 35.20, 
103.20, 105.40 (d, JC-C-F = 26.3 Hz), 108.77, 109.54 (d, JC-C-F = 
21.0 Hz), 114.52 (d, JC4-F = 2.3 Hz), 118.54, 130.43 (d, JC3-F = 
9.3 Hz), 132.10, 132.45, 140.90 (d, JC3-F = 10.9 Hz), 152.33, 
159.92, 163.35 (d, JC-F = 239.9 Hz), 165.61, 166.95, 170.63;  
MS (ESI+) m/z 456 (M+Na)+; HRMS calcd for C21H17FN4O2S 
[M+H]+: 409.1134, found: 409.1128; HPLC: tR = 10.25 min, 
96.9%. 
5.4.3. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(4-fluorophenyl)acetamide (3c) 
Yield 83%; white solid, mp 206.1–206.5 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.99 (s, 6H, 2CH3), 3.78 (s, 2H, CH2), 
6.92 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.15 (t, J = 8.6 Hz, 2H, 
Ph’H3,5), 7.40 (s, 2H, PhH3,5), 7.54-7.57 (m, 2H, Ph’H2,6), 8.54 
(d, J = 5.6 Hz, 1H, pyrimidine H6), 9.97 (s, 1H, NH); 13C NMR 
(100 MHz, DMSO-d6) δ = 15.71, 35.09, 103.18, 108.73, 115.40 
(d, JC-C-F = 22.1 Hz), 118.56, 120.44 (d, JC3-F = 7.7 Hz), 132.14, 
132.50, 135.65 (d, JC4-F = 2.4 Hz), 152.36, 156.70 (d, JC-F = 
237.8 Hz), 159.89, 165.16, 166.94, 170.69; MS (ESI+) m/z 409 
(M+H)+; HRMS calcd for C21H17FN4O2S [M+H]+: 409.1134, 
found: 409.1135; HPLC: tR = 10.09 min, 97.7%. 
5.4.4. N-(2-Chlorophenyl)-2-((4-(4-cyano-2,6-
dimethylphenoxy)pyrimidin-2-yl)thio)acetamide (3d) 
Yield 84%; white solid, mp 170.0–170.8 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 2.02 (s, 6H, 2CH3), 3.93 (s, 2H, CH2), 
6.95 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.17 (t, J = 7.6 Hz, 1H, 
Ph’H4), 7.33 (t, J = 7.8 Hz, 1H, Ph’H5), 7.47 (d, J = 8.0 Hz, 1H, 
Ph’H3), 7.56 (s, 2H, PhH3,5), 7.82 (d, J = 8.4 Hz, 1H, Ph’H6), 
8.58 (d, J = 5.6 Hz, 1H, pyrimidine H6), 9.48 (s, 1H, NH); 13C 
NMR (100 MHz, DMSO-d6) δ = 15.72, 34.91, 103.54, 108.81, 
118.48, 124.32, 124.84, 125.87, 127.52, 129.47, 132.25, 
132.66, 134.69, 152.41, 160.02, 166.24, 167.02, 170.31; MS 
(ESI+) m/z 458 (M+Na)+; HRMS calcd for C21H17ClN4O2S 
[M+Na]+: 447.0658, found: 447.0658; HPLC: tR = 10.31 min, 
96.3%. 
5.4.5. N-(3-Chlorophenyl)-2-((4-(4-cyano-2,6-
dimethylphenoxy)pyrimidin-2-yl)thio)acetamide (3e) 
Yield 78%; white solid, mp 200.0–200.8 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.97 (s, 6H, 2CH3), 3.77 (s, 2H, CH2), 
6.93 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.12 (d, J = 7.2 Hz, 
1H, Ph’H4), 7.34-7.36 (m, 4H, PhH3,5 + Ph’H5,6), 7.76 (s, 1H, 
Ph’H2), 8.54 (d, J = 5.6 Hz, 1H, pyrimidine H6), 10.09 (s, 1H, 
NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.73, 35.19, 
103.20, 108.75, 117.15, 118.22, 118.51, 122.90, 130.45, 
132.09, 132.45, 133.13, 140.65, 152.32, 159.92, 165.63, 
166.93, 170.61; MS (ESI+) m/z 425 (M+H)+; HRMS calcd for 
C21H17ClN4O2S [M+Na]+: 447.0658, found: 447.0646; HPLC: 
tR = 9.47 min, 97.4%. 
5.4.6. N-(4-Chlorophenyl)-2-((4-(4-cyano-2,6-
dimethylphenoxy)pyrimidin-2-yl)thio)acetamide (3f) 
Yield 84%; white solid, mp 176.0–176.4 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.98 (s, 6H, 2CH3), 3.77 (s, 2H, CH2), 
6.92 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.35-7.37 (m, 4H, 
PhH3,5 + Ph’H3,5), 7.55-7.57 (d, J = 8.8 Hz, 2H, Ph’H2,6), 8.53 
(d, J = 5.6 Hz, 1H, pyrimidine H6), 10.05 (s, 1H, NH); 13C 
NMR (100 MHz, DMSO-d6) δ = 15.77, 35.21, 103.26, 108.78, 
118.63, 120.35, 126.77, 128.70, 132.20, 132.54, 138.23, 
152.41, 159.96, 165.48, 167.00, 170.68; MS (ESI+) m/z 447 
(M+Na)+; HRMS calcd for C21H17ClN4O2S [M+H]+: 425.0839, 
found: 425.0838; HPLC: tR = 10.81 min, 96.0%. 
5.4.7. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(2,4-dichlorophenyl)acetamide (3g) 
Yield 77%; white solid, mp 188.8–189.5 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 2.02 (s, 6H, 2CH3), 3.93 (s, 2H, CH2), 
6.94 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.41 (d, J = 8.4 Hz, 
1H, Ph’H5), 7.56 (s, 2H, PhH3,5), 7.64 (s, 1H, Ph’H3), 7.83 (d, J 
= 8.8 Hz, 1H, Ph’H6), 8.57 (d, J = 5.6 Hz, 1H, pyrimidine H6), 
9.56 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.73, 
34.90, 103.53, 108.78, 118.46, 125.34, 125.72, 127.62, 128.86, 
128.92, 132.26, 132.65, 133.93, 152.42, 160.01, 166.43, 
167.01, 170.31; MS (ESI+) m/z 481 (M+Na)+; HRMS calcd for 
C21H16Cl2N4O2S [M+Na]+: 481.0269, found: 481.0265; HPLC: 
tR = 12.21 min, 97.6%. 
5.4.8 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(3,4-dichlorophenyl)acetamide (3h) 
Yield 85%; white solid, mp 203.6–204.3 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.98 (s, 6H, 2CH3), 3.77 (s, 2H, CH2), 
6.94 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.36 (s, 2H, PhH3,5), 
7.42 (d, J = 8.8 Hz, 1H, Ph’H5), 7.56 (d, J = 8.8 Hz, 1H, Ph’H6), 
7.90 (s, 1H, Ph’H2), 8.54 (d, J = 5.6 Hz, 1H, pyrimidine H6), 
10.19 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.71, 
35.18, 103.23, 108.73, 118.49, 118.79, 119.95, 124.62, 130.71, 
131.06, 132.12, 132.44, 139.25, 152.34, 159.93, 165.78, 
166.94, 170.53; MS (ESI+) m/z 481 (M+Na)+; HRMS calcd for 
C21H16Cl2N4O2S [M+Na]+: 481.0269, found: 481.0262; HPLC: 
tR = 11.46 min, 97.5%. 
5.4.9. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(3,5-dichlorophenyl)acetamide (3i) 
Yield 84%; white solid, mp 226.9–227.7 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.97 (s, 6H, 2CH3), 3.75 (s, 2H, CH2), 
6.94 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.29-7.33 (m, 3H, 
PhH3,5 + Ph’H4), 7.58 (s, 2H, Ph’H2,6), 8.54 (d, J = 5.6 Hz, 1H, 
pyrimidine H6), 10.22 (s, 1H, NH); 13C NMR (100 MHz, 
DMSO-d6) δ = 15.71, 35.22, 103.25, 108.73, 116.90, 118.40, 
122.49, 132.09, 132.40, 134.19, 141.44, 152.31, 159.96, 
165.97, 166.94, 170.49; MS (ESI+) m/z 481 (M+Na)+; HRMS 
calcd for C21H16Cl2N4O2S [M+H]+: 459.0449, found: 459.0434; 
HPLC: tR = 11.78 min, 98.1%. 
5.4.10. N-(4-Bromophenyl)-2-((4-(4-cyano-2,6-
dimethylphenoxy)pyrimidin-2-yl)thio)acetamide (3j) 
Yield 86%; white solid, mp 160.7–161.5 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.98 (s, 6H, 2CH3), 3.78 (s, 2H, CH2), 
6.92 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.38 (s, 2H, PhH3,5 ), 
7.48-7.53 (m, 4H, Ph’H2,3,5,6), 8.53 (d, J = 5.6 Hz, 1H, 
pyrimidine H6), 10.06 (s, 1H, NH); 13C NMR (100 MHz, 
DMSO-d6) δ = 15.75, 35.22, 103.22, 108.76, 114.73, 118.60, 
120.69, 131.58, 132.17, 132.51, 138.62, 152.38, 159.93, 
165.48, 166.96, 170.65; MS (ESI+) m/z 469 (M+H)+; HRMS 
calcd for C21H17BrN4O2S [M+H]+: 469.0334, found: 469.0338; 
HPLC: tR = 11.05 min, 97.1%. 
5.4.11. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(2-nitrophenyl)acetamide (3k) 
Yield 85%; yellow solid, mp 180.9–181.5 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.99 (s, 6H, 2CH3), 3.89 (s, 2H, CH2), 
6.96 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.36 (t, J = 7.0 Hz, 1H, 
Ph’H4), 7.53 (s, 2H, PhH3,5), 7.75 (t, J = 6.4 Hz, 1H, Ph’H5), 
7.97-8.05 (m, 2H, Ph’H3,6), 8.57 (d, J = 5.6 Hz, 1H, pyrimidine 
H6), 10.52 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) δ = 
15.69, 35.14, 103.71, 108.81, 118.53, 123.79, 124.84, 125.36, 
132.10, 132.29, 132.65, 134.84, 139.83, 152.47, 160.07, 
166.43, 167.10, 169.92; MS (ESI+) m/z 458 (M+Na)+; HRMS 
calcd for C21H17N5O4S [M+Na]+: 458.0899, found: 458.0887; 
HPLC: tR = 10.85 min, 97.3%. 
5.4.12. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(3-nitrophenyl)acetamide (3l) 
Yield 84%; light yellow solid, mp 192.8–193.5 oC; 1H NMR 
(400 MHz, DMSO-d6) δ = 1.96 (s, 6H, 2CH3), 3.79 (s, 2H, 
CH2), 6.94 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.28 (s, 2H, 
PhH3,5), 7.63 (t, J = 8.0 Hz, 1H, Ph’H5), 7.82 (d, J = 7.6 Hz, 1H, 
Ph’H6), 7.93 (d, J = 8.0 Hz, 1H, Ph’H4), 8.54-8.55 (m, 2H, 
pyrimidine H6 + Ph’H2), 10.36 (s, 1H, NH); 13C NMR (100 
MHz, DMSO-d6) δ = 15.70, 35.20, 103.25, 108.63, 112.80, 
117.78, 118.47, 124.66, 130.25, 132.11, 132.41, 140.33, 
148.01, 152.37, 159.95, 165.97, 166.98, 170.58; MS (ESI+) m/z 
436 (M+H)+; HRMS calcd for C21H17N5O4S [M+H]+: 436.1079, 
found: 436.1070; HPLC: tR = 9.98 min, 96.4%. 
5.4.13. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(4-nitrophenyl)acetamide (3m) 
Yield 85%; white solid, mp 208.7–209.5 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.97 (s, 6H, 2CH3), 3.82 (s, 2H, CH2), 
6.94 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.34 (s, 2H, PhH3,5), 
7.74 (d, J = 8.8 Hz, 2H, Ph’H2,6), 8.23 (d, J = 9.2 Hz, 2H, 
Ph’H3,5), 8.54 (d, J = 5.6 Hz, 1H, pyrimidine H6), 10.50 (s, 1H, 
NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.69, 35.37, 
103.26, 108.69, 118.44, 118.54, 125.05, 132.08, 132.47, 
142.16, 145.29, 152.32, 159.93, 166.20, 166.96, 170.49; MS 
(ESI+) m/z 458 (M+Na)+; HRMS calcd for C21H17N5O4S 
[M+H]+: 436.1079, found: 436.1061; HPLC: tR = 10.04 min, 
97.2%. 
5.4.14. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(4-cyanophenyl)acetamide (3n) 
Yield 82%; white solid, mp 209.0–209.4 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.96 (s, 6H, 2CH3), 3.79 (s, 2H, CH2), 
6.93 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.31 (s, 2H, PhH3,5), 
7.68 (d, J = 8.4 Hz, 2H, Ph’H3,5), 7.77 (d, J = 8.4 Hz, 2H, 
Ph’H2,6), 8.53 (d, J = 5.6 Hz, 1H, pyrimidine H6), 10.32 (s, 1H, 
NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.77, 35.38, 
103.33, 105.02, 108.76, 118.63, 118.88, 119.24, 132.18, 
132.51, 133.42, 143.41, 152.41, 160.01, 166.13, 167.04, 
170.59; MS (ESI+) m/z 438 (M+Na)+; HRMS calcd for 
C22H17N5O2S [M+H]+: 416.1181, found: 416.1170; HPLC: tR = 
9.57 min, 98.3%. 
5.4.15. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(4-cyano-2-fluorophenyl)acetamide (3o) 
Yield 85%; white solid, mp 217.7–218.2 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.98 (s, 6H, 2CH3), 3.88 (s, 2H, CH2), 
6.94 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.35 (s, 2H, PhH3,5), 
7.66 (d, J = 8.4 Hz, 1H, Ph’H3),  7.87 (d, J = 11.2 Hz, 1H, 
Ph’H5), 8.26 (t, J = 8.2 Hz, 1H, Ph’H6), 8.53 (d, J = 5.6 Hz, 1H, 
pyrimidine H6), 10.10 (s, 1H, NH); 13C NMR (100 MHz, 
DMSO-d6) δ = 15.81, 35.35, 103.41, 105.67 (d, JC3-F = 9.5 Hz), 
108.64, 118.09, 118.47, 119.44 (d, JC-C-F = 23.2 Hz), 121.90 (d, 
JC-C-F = 22.0 Hz), 129.60 (d, JC4-F = 2.9 Hz), 131.68 (d, JC3-F = 
11.0 Hz), 132.24, 132.51, 149.92 (d, JC-F = 246.0 Hz), 152.46, 
159.99, 166.83, 167.05, 170.59; MS (ESI+) m/z 456 (M+Na)+; 
HRMS calcd for C22H16FN5O2S [M+H]+: 434.1087, found: 
434.1071; HPLC: tR = 10.15 min, 97.0%. 
5.4.16. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(4-sulfamoylphenyl)acetamide (3p) 
Yield 77%; white solid, mp 250.9–251.5 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.97 (s, 6H, 2CH3), 3.82 (s, 2H, CH2), 
6.93 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.28 (s, 2H, NH2), 7.38 
(s, 2H, PhH3,5), 7.68 (d, J = 8.8 Hz, 2H, Ph’H2,6), 7.77 (d, J = 
8.8 Hz 2H, Ph’H3,5), 8.54 (d, J = 5.6 Hz, 1H, pyrimidine H6), 
10.28 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.74, 
35.27, 103.23, 108.80, 118.35, 118.59, 126.70, 132.15, 132.52, 
138.35, 142.07, 152.35, 159.94, 165.92, 166.93, 170.56; MS 
(ESI+) m/z 492 (M+Na)+; HRMS calcd for C21H19N5O4S2 
[M+H]+: 470.0957, found: 470.0954; HPLC: tR = 7.92 min, 
97.6%. 
5.4.17. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(o-tolyl)acetamide (3q) 
Yield 84%; white solid, mp 167.6–168.4 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 2.05 (s, 6H, 2CH3), 2.14 (s, 3H, CH3), 
3.92 (s, 2H, CH2), 6.91 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.07 
(t, J = 7.0 Hz, 1H, Ph’H4), 7.13-7.20 (m, 2H, Ph’H5,6), 7.40 (d, J 
= 7.6 Hz, 1H, Ph’H3), 7.60 (s, 2H, PhH3,5), 8.56 (d, J = 5.6 Hz, 
1H, pyrimidine H6), 9.33 (s, 1H, NH); 13C NMR (100 MHz, 
DMSO-d6) δ = 15.79, 17.79, 34.85, 103.36, 108.81, 118.53, 
124.38, 125.15, 125.99, 130.38, 131.07, 132.38, 132.74, 
136.20, 152.49, 159.97, 165.94, 166.99, 170.68; MS (ESI+) m/z 
405 (M+H)+; HRMS calcd for C22H20N4O2S [M+H]+: 405.1385, 
found: 405.1374; HPLC: tR = 10.46 min, 97.2%. 
5.4.18. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(p-tolyl)acetamide (3r) 
Yield 85%; white solid, mp 195.8–196.3 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.98 (s, 6H, 2CH3), 2.26 (s, 3H, CH3), 
3.77 (s, 2H, CH2), 6.91 (d, J = 5.2 Hz, 1H, pyrimidine H5), 7.10 
(d, J = 7.6 Hz, 2H, Ph’H3,5), 7.39 (s, 2H, PhH3,5), 7.42 (d, J = 
8.0 Hz, 2H, Ph’H2,6), 8.53 (d, J = 5.6 Hz, 1H, pyrimidine H6), 
9.84 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.76, 
20.52, 35.18, 103.20, 108.79, 118.62, 118.80, 129.13, 132.11, 
132.19, 132.56, 136.78, 152.39, 159.91, 165.04, 166.96, 
170.78; MS (ESI+) m/z 405 (M+H)+; HRMS calcd for 
C22H20N4O2S [M+Na]+: 427.1205, found: 427.1200; HPLC: tR 
= 10.62 min, 97.8%. 
5.4.19. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(2-methyl-4-sulfamoylphenyl)acetamide (3s) 
Yield 84%; white solid, mp 222.8–223.6 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 2.04 (s, 6H, 2CH3), 2.25 (s, 3H, CH3), 
3.97 (s, 2H, CH2), 6.92 (d, J = 5.6 Hz, 1H, pyrimidine H5), 7.27 
(s, 2H, NH2), 7.59 (s, 2H, PhH3,5), 7.61-7.72 (m, 3H, Ph’H3,5,6), 
8.56 (d, J = 5.6 Hz, 1H, pyrimidine H6), 9.50 (s, 1H, NH); 13C 
NMR (100 MHz, DMSO-d6) δ = 15.78, 17.93, 34.96, 103.37, 
108.78, 118.50, 123.39, 123.71, 127.69, 130.64, 132.32, 
132.70, 139.34, 139.87, 152.45, 159.97, 166.33, 166.97, 
170.56; MS (ESI+) m/z 409 (M+H)+; HRMS calcd for 
C22H21N5O4S2 [M+H]+: 484.1113, found: 484.1115; HPLC: tR = 
8.45 min, 98.4%. 
5.4.20. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(4-methoxyphenyl)acetamide (3t) 
Yield 86%; white solid, mp 184.5–185.3 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.99 (s, 6H, 2CH3), 3.73 (s, 3H, CH3), 
3.77 (s, 2H, CH2), 6.87 (d, J = 8.8 Hz, 2H, Ph’H3,5), 6.91 (d, J = 
5.6 Hz, 1H, pyrimidine H5), 7.42-7.47 (m, 4H, PhH3,5 + 
Ph’H2,6), 8.54 (d, J = 5.6 Hz, 1H, pyrimidine H6), 9.80 (s, 1H, 
NH); 13C NMR (100 MHz, DMSO-d6) δ = 15.74, 35.07, 55.19, 
103.17, 108.76, 113.85, 118.60, 120.25, 132.18, 132.47, 
132.55, 152.39, 155.14, 159.89, 164.76, 166.95, 170.78; MS 
(ESI+) m/z 421 (M+H)+; HRMS calcd for C22H20N4O3S 
[M+H]+: 421.1334, found: 421.1332; HPLC: tR = 9.74 min, 
96.9%. 
5.4.21. 2-((4-(4-Cyano-2,6-dimethylphenoxy)pyrimidin-2-
yl)thio)-N-(4-hydroxyphenyl)acetamide (3u) 
Yield 80%; white solid, mp 199.4–200.2 oC; 1H NMR (400 
MHz, DMSO-d6) δ = 1.99 (s, 6H, 2CH3), 3.75 (s, 2H, CH2), 
6.69 (d, J = 8.4 Hz, 2H, Ph’H3,5), 6.91 (d, J = 5.6 Hz, 1H, 
pyrimidine H5), 7.32 (d, J = 8.4 Hz, 2H, Ph’H2,6), 7.43 (s, 2H, 
PhH3,5), 8.53 (d, J = 5.6 Hz, 1H, pyrimidine H6), 9.21 (s, 1H, 
OH), 9.68 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) δ = 
15.75, 35.05, 103.15, 108.77, 115.06, 118.61, 120.47, 131.02, 
132.19, 132.58, 152.39, 153.25, 159.88, 164.54, 166.94, 
170.81; MS (ESI+) m/z 407 (M+H)+; HRMS calcd for 
C21H18N4O3S [M+H]+: 407.1178, found: 407.1167; HPLC: tR = 
8.18 min, 97.9%. 
5.5. Anti-HIV activity assay 
The anti-HIV activity and cytotoxicity of the compounds 3a-
u were evaluated against wild-type HIV-1 strain IIIB, a double 
RT mutant (K103N + Y181C) HIV-1 strain and HIV-2 strain 
ROD in MT-4 cell cultures using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) method.12,13 
Briefly, virus stocks were titrated in MT-4 cells and expressed 
as the 50% cell culture infective dose (CCID50). MT-4 cells 
were suspended in culture medium at 1 × 105 cells/mL and 
infected with HIV at a multiplicity of infection of 0.02. 
Immediately after viral infection, 100 μL of the cell suspension 
was placed in each well of a flat-bottomed microtiter tray 
containing various concentrations of the test compounds. The 
test compounds were dissolved in DMSO at 50 mM or higher. 
After 4 days of incubation at 37 °C, the number of viable cells 
was determined using the MTT method. Compounds were 
tested in parallel for cytotoxic effects in uninfected MT-4 cells. 
5.6. HIV-1 RT assay 
Recombinant wild type p66/p51 HIV-1 RT was expressed 
and purified as the previously described procedure.9 The RT 
assay was performed with the EnzCheck Reverse Transcriptase 
Assay kit (Molecular Probes, Invitrogen), as described by the 
manufacturer. The assay was based on the dsDNA quantitation 
reagent PicoGreen. This reagent showed a pronounced increase 
in fluorescence signal upon binding to dsDNA or RNA-DNA 
heteroduplexes. Single-stranded nucleic acids generated only 
minor fluorescence signal enhancement when a sufficiently 
high dye:base pair ratio was applied.10 This condition was met 
in the assay. 
A poly(rA) template of approximately 350 bases long, and an 
oligo(dT)16 primer, were annealed in a molar ratio of 1:1.2 (60 
min, at room temperature). 52 ng of the RNA/DNA was 
brought into each well of a 96-well plate in a volume of 20 mL 
polymerization buffer (60 mM Tris-HCl, 60 mM KCl, 8 mM 
MgCl2, 13 mM DTT, 100 mM dTTP, pH = 8.1). 5.0 mL of RT 
enzyme solution, diluted to a suitable concentration in enzyme 
dilution buffer (50 mM Tris-HCl, 20% glycerol, 2 mM DTT, 
pH = 7.6), was added. The reaction mixture were incubated at 
25 oC for 40 min and then stopped by the addition of EDTA (15 
mM). Heteroduplexes were then detected by addition of 
PicoGreen. Signals were read using an excitation wavelength of 
490 nm and emission detection at 523 nm using a 
spectrofluorometer (Safire2, Tecan). To test the activity of 
compounds against RT, 1.0 mL of compound in DMSO was 
added to each well before the addition of RT enzyme solution. 
Control wells without compound contained the same amount of 
DMSO. Results were expressed as relative fluorescence, i. e. 
the fluorescence signal of the reaction mixed with compound 
divided by the signal of the same reaction mixed without 
compound. 
5.7. Molecular docking 
Molecular modeling was performed with the Tripos 
molecular modeling packages Sybyl-X 1.2. All the molecules 
for docking were built using standard bond lengths and angles 
from Sybyl-X 1.2/base Builder and were then optimized using 
the Tripos force field for 2000 generations two times or more, 
until the minimized conformers of the ligand were the same. 
The flexible docking method, called Surflex-Dock14, docks the 
ligand automatically into the ligand binding site of the receptor 
by using a protocol-based approach and an empirically-derived 
scoring function15. The protocol is a computational 
representation of a putative ligand that binds to the intended 
binding site and is a unique and essential element of the 
docking algorithm16. The scoring function in Surflex-Dock, 
which contains hydrophobic, polar, repulsive, entropic, and 
solvation terms, was trained to estimate the dissociation 
constant (Kd) expressed in -log (Kd)2. Prior to docking, the 
protein was prepared by removing water molecules, the ligand, 
and other unnecessary small molecules from the crystal 
structure of the ligand–HIV-1 RT complex (PDB code: 
3C6T)11; simultaneously, polar hydrogen atoms were added to 
the protein. Surflex-Dock default settings were used for other 
parameters, such as the number of starting conformations per 
molecule (set to 0), the size to expand search grid (set to 8 Å), 
the maximum number of rotatable bonds per molecule (set to 
100), and the maximum number of poses per ligand (set to 20). 
During the docking procedure, all of the single bonds in residue 
side-chains inside the defined RT binding pocket were regarded 
as rotatable or flexible, and the ligand was allowed to rotate at 
all single bonds and move flexibly within the tentative binding 
pocket. The atomic charges were recalculated using the 
Kollman all-atom approach for the protein and the Gasteiger-
Hückel approach for the ligand. The binding interaction energy 
was calculated, including van der Waals, electrostatic, and 
torsional energy terms defined in the Tripos force field. The 
structure optimization was performed for 20,000 generations 
using a genetic algorithm, and the 20-best-scoring ligand-
protein complexes were kept for further analyses. The -log 
(Kd)2 values of the 20-best-scoring complexes, which 
represented the binding affinities of ligand with RT, 
encompassed a wide scope of functional classes (10-2–10-9). 
Therefore, only the highest-scoring 3D structural model of the 
ligand-bound RT was chosen to define the binding interaction17. 
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